Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.

NDAQ:AGIO - Post by User

Agios Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Sep 28, 2024 7:15am

219 Views

Post# 36245171

Where are the Opportunities in (AGIO)

BREAKING NEWS: $AGIO Where are the Opportunities in (AGIO)2024-09-28 06:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...AGIO - Where are the Opportunities in (AGIO)

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec